Therapeutic Targets in Alveolar Rhabdomyosarcoma

描述(申请人提供)：实体肿瘤的进展和转移是癌症患者死亡的主要原因。儿童肌癌泡状横纹肌肉瘤就是一个典型的例子。晚期肺泡型横纹肌肉瘤患者预后不佳的原因是对疾病特定的进展机制的认识上的差距。我们对参加全国性临床试验的患者中横纹肌肉瘤基因表达的初步研究表明，血小板衍生生长因子受体A(PDGFR-A)可能是疾病进展和转移的媒介。在我们的研究中，我们发现PDGFR-A是Pax3：Fkhr的转录靶点，Pax3：Fkhr是一种易位介导的融合基因，在大多数肺泡型横纹肌肉瘤中发现。我们假设，配体依赖或结构性的PDGFR-A信号通路在泡状横纹肌肉瘤的进展和转移中起重要作用。为了验证这一假设，我们建立了有条件的小鼠肿瘤模型，真实地概括了人类肺泡型横纹肌肉瘤的原始突变和转移进展。该模型中的肿瘤对受体酪氨酸激酶抑制剂伊马替尼有显著的反应，它显著抑制PDGFR-A信号转导。我们的第一个目标是通过体外功能测试来描述横纹肌肉瘤中的PDGFR-A信号通路。在这些实验中，将检测小鼠和人的肺泡横纹肌肉瘤细胞培养物在存在或不存在PDGFR-A抑制剂或siRNA的情况下Akt、MAPK和PKC信号通路的变化。在PDGFR-A抑制条件下，将在OVO中检测转移的功能能力。我们的第二个目标是确定PDGFR-A阻断对横纹肌肉瘤的体内病理生理影响。为了实现这一目标，我们将在我们的泡状横纹肌肉瘤小鼠模型中使用PDGFR-A的条件等位基因来消除PDGFR-A信号，我们将测量在有和没有PDGFR-A信号的情况下发病、频率和进展的差异。这项研究为儿童肺泡型横纹肌肉瘤和其他肿瘤的分子治疗建立了系统、合理的遗传学方法的原则证据。 公共卫生相关性：实体肿瘤的进展和转移是癌症患者死亡的主要原因。儿童肌癌泡状横纹肌肉瘤就是一个典型的例子。晚期肺泡型横纹肌肉瘤患者预后不佳的原因是对疾病特定的进展机制的认识上的差距。这项关于血小板衍生生长因子在癌症进展中的研究为系统、合理的遗传方法在儿童肺泡型横纹肌肉瘤和其他肿瘤的分子治疗中建立了原理证明。

DESCRIPTION (provided by applicant): Progression and metastasis of solid tumors is a principal cause of death for cancer patients. The childhood muscle cancer alveolar rhabdomyosarcoma is a classic example. A gap in understanding the disease-specific mechanisms of progression underlies the dismal outcome for patients with advanced alveolar rhabdomyosarcoma. Our initial studies of rhabdomyosarcoma gene expression amongst patients enrolled in a national clinical trial suggest that the platelet-derived growth factor receptor A (PDGFR-A) may be a mediator of disease progression and metastasis. In our studies PDGFR-A has been found to be a transcriptional target of Pax3:Fkhr, the translocation-mediated fusion gene found in the majority of alveolar rhabdomyosarcomas. We hypothesize that ligand-dependent or constitutive PDGFR-A signaling pathways play a prominent role in progression and metastasis of alveolar rhabdomyosarcoma. To test this hypothesis, we have generated conditional mouse tumor models that authentically recapitulate the primary mutations and the metastatic progression of alveolar rhabdomyosarcomas in humans. Tumors in this model have dramatic responses to the receptor tyrosine kinase inhibitor, Imatinib, which significantly inhibits PDGFR-A signaling. Our first aim is to delineate the PDGFR-A signaling pathway in rhabdomyosarcoma by functional testing in vitro. For these experiments, mouse and human alveolar rhabdomyosarcoma cell cultures will be examined for alterations of the Akt, MAPK, and PKC signaling pathways in the presence or absence of PDGFR-A inhibitors or siRNA. The functional ability to metastasize under PDGFR-A inhibitory conditions will be assayed in ovo. Our second aim is to determine the pathophysiological impact of PDGFR-A blockade for rhabdomyosarcoma in vivo. To achieve this aim, we will use a conditional allele of PDGFR-A to abrogate PDGFR-A signaling in our mouse model of alveolar rhabdomyosarcoma, and we will measure the differences in onset, frequency, and progression with and without PDGFR-A signaling. This study establishes proof-of-principal for a systematic, rational genetic approach to molecular therapeutics in childhood alveolar rhabdomyosarcomas and other tumors. PUBLIC HEALTH RELEVANCE: Progression and metastasis of solid tumors is a principal cause of death for cancer patients. The childhood muscle cancer alveolar rhabdomyosarcoma is a classic example. A gap in understanding the disease-specific mechanisms of progression underlies the dismal outcome for patients with advanced alveolar rhabdomyosarcoma. This study of platelet-derived growth factors in cancer progression establishes proof-of- principal for a systematic, rational genetic approach to molecular therapeutics in childhood alveolar rhabdomyosarcomas and other tumors.